Company Overview

Numinus Wellness Inc. is a mental health care company focused on psychedelic‑assisted therapy and innovative behavioral health services. The company operates in the mental health services, healthcare clinics, and psychedelic research and development industries, with an emphasis on integrating psychedelic‑assisted therapies into regulated clinical settings. Its core activities combine clinical care, practitioner training, and research infrastructure to address conditions such as depression, anxiety, post‑traumatic stress disorder, and substance use disorders.

Founded in 2018, Numinus initially focused on laboratory testing and research services for psychedelic compounds before expanding into clinical care. Over time, it evolved into a vertically integrated platform offering therapeutic services, clinical trials support, and professional training. The company positions itself as an early mover in regulated psychedelic therapy, leveraging licensed clinical infrastructure and compliance experience as barriers to entry in an emerging sector.

Business Operations

Numinus generates revenue primarily through its Clinical Services, Practitioner Training, and Research & Laboratory Services business lines. The Clinical Services segment operates outpatient mental health clinics providing traditional psychotherapy alongside ketamine‑assisted therapy where permitted by regulation. Practitioner Training focuses on educating licensed healthcare professionals in psychedelic‑assisted therapy protocols, while Research & Laboratory Services support clinical trials, compound testing, and data collection for third parties.

Operations are primarily based in Canada, with additional activities in the United States related to training programs and research collaborations. The company controls a network of owned and operated clinics, proprietary training curricula, and laboratory capabilities. Numinus has pursued partnerships with academic institutions and nonprofit organizations involved in psychedelic research; however, the depth and commercial impact of certain collaborations are not consistently disclosed, and some details are inconclusive based on available public sources.

Strategic Position & Investments

Numinus’s strategy centers on scaling regulated clinical infrastructure ahead of broader regulatory change in psychedelic medicines. Growth initiatives include expanding clinic locations, increasing therapist training capacity, and aligning services with late‑stage clinical research programs so therapies can be rapidly commercialized if approved by regulators. The company has also emphasized integration with evidence‑based treatment models to support payer and institutional adoption.

Historically, Numinus has made targeted acquisitions to accelerate clinical scale and training capabilities, including the acquisition of Mindspace Psychology (now integrated into its clinic network). The company has also invested in intellectual property, clinical protocols, and data systems related to psychedelic‑assisted therapy. Its strategic exposure includes emerging therapies such as MDMA‑assisted and psilocybin‑assisted treatment, though commercial deployment of these therapies remains subject to regulatory approval; timelines and outcomes are therefore uncertain.

Geographic Footprint

Numinus is headquartered in Vancouver, British Columbia, and maintains its strongest operational presence across Canada, where it operates clinics and laboratory facilities under existing healthcare regulations. Canadian operations represent the majority of current clinical revenue and infrastructure.

The company also has a growing footprint in the United States, primarily through training programs, research support, and strategic relationships tied to U.S.‑based clinical trials. While Numinus positions itself as a North American platform, it does not currently report material operating revenue from regions outside North America, and international expansion beyond this region remains limited based on publicly available disclosures.

Leadership & Governance

Numinus was founded by Payton Nyquvest, who has been central to shaping its strategy around regulated psychedelic care and clinical credibility. The leadership team emphasizes a medicalized, compliance‑first approach, aiming to integrate novel therapies into mainstream healthcare systems rather than consumer or retreat‑based models.

Key executives include:

• Payton Nyquvest – Founder and Chief Executive Officer
• Sharan Sidhu – Chief Financial Officer
• Dr. Joe Flanders – Chief Medical Officer

Leadership roles and responsibilities have evolved as the company has restructured and scaled; some executive positions and titles have changed over time, and disclosures outside of formal filings may vary.